
Kristine Ball
President & CEO, Antiva BiosciencesKristine is President and Chief Executive Officer at Antiva Biosciences and is our Audit Chair of the Board of Directors.
With more than 20 years of biopharma industry expertise, she has extensive leadership experience in the life sciences industry. She is currently President & CEO of Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of high-risk infections and pre-cancerous lesions caused by human papilloma virus. She most recently served as Chief Executive Officer at Soteria Biotherapeutics. Prior to Soteria, she served as SVP, Corporate Strategy, and CFO of Menlo Therapeutics, which later became VYNE Therapeutics, where she was responsible for leading all non-R&D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology. Prior to joining Menlo, she held a variety of senior finance roles in the life sciences industry, including SVP and CFO of Relypsa, SVP of Finance & Administration, and CFO of KAI Pharmaceuticals, and VP of Finance at Exelixis.
She previously served on the board of directors of Soteria, Atreca, and Forty Seven, a Nasdaq-listed biotechnology company that was later acquired by Gilead Sciences.
Kristine holds a BS from Babson College